Grifols, S.A. $GRFS Shares Sold by Anthracite Investment Company Inc.

Anthracite Investment Company Inc. cut its holdings in Grifols, S.A. (NASDAQ:GRFS) by 82.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,688 shares of the biotechnology company’s stock after selling 419,147 shares during the period. Anthracite Investment Company Inc.’s holdings in Grifols were worth $784,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Grifols in the second quarter valued at $95,000. Ballentine Partners LLC acquired a new stake in shares of Grifols during the first quarter worth about $77,000. Ascent Group LLC acquired a new stake in shares of Grifols during the second quarter worth about $141,000. Cerity Partners LLC increased its position in shares of Grifols by 22.8% during the first quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 4,129 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Grifols during the first quarter worth about $184,000.

Analyst Ratings Changes

A number of research firms have recently commented on GRFS. Zacks Research upgraded Grifols to a “hold” rating in a research report on Friday, August 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research report on Saturday. Wall Street Zen cut Grifols from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.30.

Grifols Stock Performance

Shares of GRFS stock opened at $9.46 on Friday. The stock has a market capitalization of $6.50 billion, a PE ratio of 45.05, a price-to-earnings-growth ratio of 0.32 and a beta of 0.69. Grifols, S.A. has a 52-week low of $6.19 and a 52-week high of $11.14. The stock’s 50-day moving average price is $9.80 and its 200 day moving average price is $9.07. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20.

Grifols Announces Dividend

The business also recently declared a special dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were given a $0.1404 dividend. The ex-dividend date was Tuesday, August 12th. Grifols’s payout ratio is 66.67%.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.